EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Taxifolin: From Racemic Ambiguity to Stereospecific Pharmacological Precision: A Systematic Review of Isomeric Efficacy

Harsimran Singh, Rohit Kumar

Journal for Research in Applied Sciences and Biotechnology · 16.08.2026 · 5 (4) · 16-23

DOI: 10.55544/jrasb.5.4.3 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal for Research in Applied Sciences and Biotechnology, online erschienen am 16.08.2026. Verfasst von Harsimran Singh und 1 weiteren Autor:innen. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Taxifolin (dihydroquercetin), a naturally occurring flavanonol, has attracted increasing scientific interest because of its broad neuroprotective, antioxidant, and anti-inflammatory properties. Despite extensive experimental evidence supporting its therapeutic potential, the pharmacological translation of taxifolin remains limited by poor bioavailability, rapid metabolism, and the widespread use of undefined racemic mixtures in research. The saturated C2–C3 bond in Taxifolin creates multiple stereoisomers, yet most published studies fail to evaluate stereospecific pharmacodynamic and pharmacokinetic differences, leading to inconsistent biological outcomes. This systematic review summarizes current evidence regarding the stereochemical, pharmacological, and translational aspects of Taxifolin in neurodegenerative disorders and traumatic brain injury (TBI). Experimental findings from in vitro and in vivo studies demonstrate that Taxifolin exerts neuroprotective effects through modulation of oxidative stress, neuroinflammation, mitochondrial dysfunction, and apoptotic signaling. The compound activates antioxidant pathways, including Nrf2/HO-1 and PI3K/Akt, while suppressing inflammatory mediators such as NF-κB, JAK/STAT3, MAPKs, and the NLRP3 inflammasome. Taxifolin also reduces amyloid-β aggregation, preserves synaptic integrity, and improves cognitive performance in experimental models. Pharmacokinetic investigations indicate stereoselective differences between isomers, with the (2R,3R)-isomer showing superior tissue retention and therapeutic activity compared to other stereoisomeric forms. Recent advances in nanomedicine-based delivery systems, including nanoparticles and phospholipid complexes, have demonstrated improved brain targeting and enhanced bioavailability. This review highlights the importance of stereochemical precision, targeted drug delivery, and mechanistic multi-pathway modulation in advancing Taxifolin from a nutraceutical compound toward a clinically relevant neuroprotective therapy.

Zitieren

APA

Singh, H., & Kumar, R. (2026). Taxifolin: From Racemic Ambiguity to Stereospecific Pharmacological Precision: A Systematic Review of Isomeric Efficacy. Journal for Research in Applied Sciences and Biotechnology, 5(4), 16-23. https://doi.org/10.55544/jrasb.5.4.3

Vancouver

Singh H, Kumar R. Taxifolin: From Racemic Ambiguity to Stereospecific Pharmacological Precision: A Systematic Review of Isomeric Efficacy. Journal for Research in Applied Sciences and Biotechnology. 2026;5(4):16-23. doi:10.55544/jrasb.5.4.3

BibTeX
@article{Singh2026,
  author = {Singh, Harsimran and Kumar, Rohit},
  title = {Taxifolin: From Racemic Ambiguity to Stereospecific Pharmacological Precision: A Systematic Review of Isomeric Efficacy},
  journal = {Journal for Research in Applied Sciences and Biotechnology},
  year = {2026},
  volume = {5},
  number = {4},
  pages = {16--23},
  doi = {10.55544/jrasb.5.4.3}
}
Kostenlos starten →